Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

    NEXT STORY
    Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
    PREV STORY
    BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    assessURhealth, LLC Partners with athenahealth’s ‘More Disruption Please’ Program to Enhance Access to Mental and Behavioral Health Screening Tools

    Tampa, FL, Dec. 12, 2017 (GLOBE NEWSWIRE) -- assessURhealth, LLC, a provider of mental ...

    author_avatar
    NASDAQ Market News

    Amoxicillin Market To Reach USD 4,962.6 Million By 2026 | Reports And Data

    author_avatar
    NASDAQ Market News

    Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term

    Lisbon, Portugal, 12 September 2017 ­­­- Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ...

    author_avatar
    NASDAQ Market News